Alexion Pharmaceuticals (ALXN) : Para Advisors added new position in Alexion Pharmaceuticals during the most recent quarter end. The investment management firm now holds 7,500 shares of Alexion Pharmaceuticals which is valued at $852,150 , the company said in a statement filed on Nov 14, 2016 with the SEC.Alexion Pharmaceuticals makes up approximately 9.15% of Para Advisors’s portfolio.
Other Hedge Funds, Including , Capital Research Global Investors reduced its stake in ALXN by selling 10,284,191 shares or 40.19% in the most recent quarter. The Hedge Fund company now holds 15,305,131 shares of ALXN which is valued at $1,819,627,025. Alexion Pharmaceuticals makes up approx 0.65% of Capital Research Global Investors’s portfolio.Diam Ltd. reduced its stake in ALXN by selling 17,722 shares or 15.12% in the most recent quarter. The Hedge Fund company now holds 99,525 shares of ALXN which is valued at $11,947,976. Alexion Pharmaceuticals makes up approx 0.19% of Diam Ltd.’s portfolio.Winslow Capital Management reduced its stake in ALXN by selling 26 shares or 7.54% in the most recent quarter. The Hedge Fund company now holds 319 shares of ALXN which is valued at $40,749.Sumitomo Life Insurance Co reduced its stake in ALXN by selling 1,167 shares or 10.81% in the most recent quarter. The Hedge Fund company now holds 9,624 shares of ALXN which is valued at $1,168,450. Alexion Pharmaceuticals makes up approx 0.18% of Sumitomo Life Insurance Co’s portfolio.Louisiana State Employees Retirement System reduced its stake in ALXN by selling 400 shares or 2.72% in the most recent quarter. The Hedge Fund company now holds 14,300 shares of ALXN which is valued at $1,736,163. Alexion Pharmaceuticals makes up approx 0.09% of Louisiana State Employees Retirement System’s portfolio.
Alexion Pharmaceuticals closed down -3.12 points or -2.54% at $119.85 with 15,23,614 shares getting traded on Monday. Post opening the session at $122.49, the shares hit an intraday low of $119.7 and an intraday high of $124.04 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alexion Pharmaceuticals reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $1.17. The company had revenue of $799.10 million for the quarter, compared to analysts expectations of $786.61 million. The company’s revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Deutsche Bank Initiated Alexion Pharmaceuticals on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $164.Alexion Pharmaceuticals was Upgraded by Goldman to ” Buy” on Oct 28, 2016. Company shares were Reiterated by Wedbush on Oct 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 135 from a previous price target of $132 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.